Skip to main content
SpringerLink
Log in

mTOR Signaling is Involved in Indomethacin and Nimesulide Suppression of Colorectal Cancer Cell Growth via a COX-2 Independent Pathway

  • Translational Research and Biomarkers
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

Inhibition of mammalian target of rapamycin (mTOR) represents an attractive target for anticancer therapy, but its role in suppression of colorectal cancer (CRC) cell growth by cyclooxygenase-2 (COX-2) inhibitors is unclear. Here, we analyzed the effect of indomethacin (Indo, a nonselective COX-2 inhibitor) and nimesulide (Nim, a selective COX-2 inhibitor) on mTOR signaling in CRC cells in vitro and in vivo to determine the dependence of this effect on COX-2.

Methods

Human CRC cell lines with varying COX-2 expression levels were treated with Indo and Nim. Western blot test was performed to detect mTOR-related components (mTOR, p70s6 K, and 4EBP1), and cell viability, cell cycle, and apoptosis were assessed. HCT116 and SW1116 cells were injected into athymic nude mice to establish a CRC xenograft model. After treatment with Nim, tumor volume, mTOR signaling, and apoptosis were evaluated in this model. HT29 and SW1116 cells were also treated with Nim after transfection with COX-2-specific small interfering RNA (siRNA) to assess dependence of COX-2 on mTOR signaling under drug treatment.

Results

Both Indo and Nim reduced mTOR signaling activity in CRC cells that differ in their COX-2 expression in vitro and in vivo. Additionally, Indo and Nim could reduce the mTOR signaling activity after COX-2 silencing in CRC cells.

Conclusions

mTOR signaling is involved in Indo- and Nim-mediated suppression of CRC growth via a COX-2 independent pathway. This study unveils a novel mechanism through which COX-2 inhibitors exerts their anticancer effects and further emphasizes targeting mTOR signaling in anticancer therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Tsang CK, Zheng XF. TOR-in(g) the nucleus. Cell Cycle. 2007;6:25–9.

    Article  CAS  PubMed  Google Scholar 

  2. Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev. 2004;18:1926–45.

    Article  CAS  PubMed  Google Scholar 

  3. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell. 2007;12:9–22.

    Article  CAS  PubMed  Google Scholar 

  4. Tsang CK, Qi H, Liu LF, Zheng XF. Targeting mammalian target of rapamycin (mTOR) for health and diseases. Drug Discov Today. 2007;12:112–24.

    Article  CAS  PubMed  Google Scholar 

  5. Gibbons JJ, Abraham RT, Yu K. Mammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth. Semin Oncol. 2009;36(Suppl 3):S3–17.

    Article  CAS  PubMed  Google Scholar 

  6. Zhang YJ, Dai Q, Tian XQ, et al. mTOR signaling pathway is a target for the treatment of colorectal cancer. Ann Surg Oncol. 2009;16:2617–28.

    Article  PubMed  Google Scholar 

  7. Zhang YJ, Tian XQ, Sun DF, et al. Combined inhibition of MEK and mTOR signaling inhibits initiation and progression of colorectal cancer. Cancer Invest. 2009;27:273–85.

    Article  CAS  PubMed  Google Scholar 

  8. Sarkar FH, Adsule S, Li Y, Padhye S. Back to the future: COX-2 inhibitors for chemoprevention and cancer therapy. Mini Rev Med Chem. 2007;7:599–608.

    Article  CAS  PubMed  Google Scholar 

  9. Grösch S, Maier TJ, Schiffmann S, Geisslinger G. Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. J Natl Cancer Inst. 2006;98:736–47.

    Article  PubMed  Google Scholar 

  10. Kashfi K, Rigas B. Non-COX-2 targets and cancer: expanding the molecular target repertoire of chemoprevention. Biochem Pharmacol. 2005;70:969–86.

    Article  CAS  PubMed  Google Scholar 

  11. Jana NR. NSAIDs and apoptosis. Cell Mol Life Sci. 2008;65:1295–301.

    Article  CAS  PubMed  Google Scholar 

  12. Ghosh M, Wang H, Ai Y, et al. COX-2 suppresses tissue factor expression via endocannabinoid-directed PPARdelta activation. J Exp Med. 2007;204:2053–61.

    Article  CAS  PubMed  Google Scholar 

  13. Yamauchi T, Watanabe M, Hasegawa H, et al. The potential for a selective cyclooxygenase-2 inhibitor in the prevention of liver metastasis in human colorectal cancer. Anticancer Res. 2003;23:245–9.

    CAS  PubMed  Google Scholar 

  14. Zhang YJ, Dai Q, Wu SM, et al. Susceptibility for NSAIDs-induced apoptosis correlates to p53 gene status in gastric cancer cells. Cancer Invest. 2008;26:868–77.

    Article  CAS  PubMed  Google Scholar 

  15. Czembirek C, Eder-Czembirek C, Erovic BM, et al. The cyclooxygenase-2 inhibitor nimesulide, a nonsteroidal analgesic, decreases the effect of radiation therapy in head-and-neck cancer cells. Strahlenther Onkol. 2009;185:310–7.

    Article  PubMed  Google Scholar 

  16. Shaik MS, Chatterjee A, Singh M. Effect of a selective cyclooxygenase-2 inhibitor, nimesulide, on the growth of lung tumors and their expression of cyclooxygenase-2 and peroxisome proliferator- activated receptor-gamma. Clin Cancer Res. 2004;10:1521–9.

    Article  CAS  PubMed  Google Scholar 

  17. Zhang YJ, Zhao SL, Tian XQ, et al. Combined inhibition of Dnmt and mTOR signaling inhibits formation and growth of colorectal cancer. Int J Colorectal Dis. 2009;24:629–39.

    Article  PubMed  Google Scholar 

  18. Hiraga T, Myoui A, Choi ME, Yoshikawa H, Yoneda T. Stimulation of cyclooxygenase-2 expression by bone-derived transforming growth factor-beta enhances bone metastases in breast cancer. Cancer Res. 2006;66:2067–73.

    Article  CAS  PubMed  Google Scholar 

  19. Parashar B, Shafit-Zagardo B. Inhibition of human neuroblastoma in SCID mice by low-dose of selective Cox-2 inhibitor nimesulide. J Neurooncol. 2006;78:129–34.

    Article  CAS  PubMed  Google Scholar 

  20. Makowski M, Grzela T, Niderla J, et al. Inhibition of cyclooxygenase-2 indirectly potentiates antitumor effects of photodynamic therapy in mice. Clin Cancer Res. 2003;9:5417–22.

    CAS  PubMed  Google Scholar 

  21. Menon S, Manning BD. Common corruption of the mTOR signaling network in human tumors. Oncogene. 2008;27(Suppl 2):S43–51.

    Article  CAS  PubMed  Google Scholar 

  22. Sudarsanam S, Johnson DE. Functional consequences of mTOR inhibition. Curr Opin Drug Discov Devel. 2010;13:31–40.

    CAS  PubMed  Google Scholar 

  23. Dancey JE, Curiel R, Purvis J. Evaluating temsirolimus activity in multiple tumors: a review of clinical trials. Semin Oncol. 2009;36(Suppl 3):S46–58.

    Article  CAS  PubMed  Google Scholar 

  24. Singleton PA, Mambetsariev N, Lennon FE, et al. Methylnaltrexone potentiates the anti-angiogenic effects of mTOR inhibitors. J Angiogenes Res. 2010;2:5.

    Google Scholar 

  25. Efferson CL, Winkelmann CT, Ware C, et al. Downregulation of Notch pathway by a γ-secretase inhibitor attenuates AKT/mammalian target of rapamycin signaling and glucose uptake in an ERBB2 transgenic breast cancer model. Cancer Res. 2010;70:2476–84.

    Article  CAS  PubMed  Google Scholar 

  26. Leng J, Han C, Demetris AJ, Michalopoulos GK, Wu T. Cyclooxygenase-2 promotes hepatocellular carcinoma cell growth through Akt activation: evidence for Akt inhibition in celecoxib-induced apoptosis. Hepatology. 2003;38:756–68.

    Article  CAS  PubMed  Google Scholar 

  27. Ladu S, Calvisi DF, Conner EA, et al. E2F1 inhibits c-Myc-driven apoptosis via PIK3CA/Akt/mTOR and COX-2 in a mouse model of human liver cancer. Gastroenterology. 2008;135:1322–32.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgment

This work was supported by grants from the National Natural Science Foundation of China (30900672) and Shanghai Rising Star Program (10QA1404300) to Y.J.Z. and grants from the Shanghai Municipal Education Commission (jdy09074) to Y.J.B.

Conflict of interest

The authors declare no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Digestion, No. 3 People’s Hospital Affiliated to Shanghai Jiaotong University, School of Medicine, Shanghai, China

    Yan-Jie Zhang MD, PhD, Yu-Jie Bao MD, Qiang Dai MD, Wen-Yan Yang MD, Peng Cheng MD, Li-Ming Zhu MD, Bi-Jun Wang MD & Fo-Hu Jiang MD

Authors
  1. Yan-Jie Zhang MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yu-Jie Bao MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Qiang Dai MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Wen-Yan Yang MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Peng Cheng MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Li-Ming Zhu MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Bi-Jun Wang MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Fo-Hu Jiang MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yan-Jie Zhang MD, PhD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zhang, YJ., Bao, YJ., Dai, Q. et al. mTOR Signaling is Involved in Indomethacin and Nimesulide Suppression of Colorectal Cancer Cell Growth via a COX-2 Independent Pathway. Ann Surg Oncol 18, 580–588 (2011). https://doi.org/10.1245/s10434-010-1268-9

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-010-1268-9

Keywords

Search

Navigation